| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Review |
Authors' Affiliation: Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
Requests for reprints: Jeffrey Schlom, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Room 8B09, 10 Center Drive, Bethesda, MD 20892. Phone: 301-496-4343; Fax: 301-496-2756; E-mail: js141c{at}nih.gov.
The field of cancer vaccines is currently in an active state of preclinical and clinical investigations. Although no therapeutic cancer vaccine has to date been approved by the Food and Drug Administration, several new paradigms are emerging from recent clinical findings both in the use of combination therapy approaches and, perhaps more importantly, in clinical trial design and end point analyses. This article will review recent clinical trials involving several different cancer vaccines from which data are emerging contrasting classic "tumor response" (Response Evaluation Criteria in Solid Tumors) criteria with "patient response" in the manifestation of increased patient survival post-vaccine therapy. Also described are several strategies in which cancer vaccines can be exploited in combination with other agents and therapeutic modalities that are quite unique when compared with "conventional" combination therapies. This is most likely due to the phenomena that (a) cancer vaccines initiate a dynamic immune process that can be exploited in subsequent therapies and (b) both radiation and certain chemotherapeutic agents have been shown to alter the phenotype of tumor cells as to render them more susceptible to T-cellmediated killing. Consequently, evidence is emerging from several studies in which patient cohorts who first receive a cancer vaccine (as contrasted with control cohorts) benefit clinically from subsequent therapies.
This article has been cited by other articles:
![]() |
G. V. Shurin, I. L. Tourkova, R. Kaneno, and M. R. Shurin Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism J. Immunol., July 1, 2009; 183(1): 137 - 144. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Keilholz, A. Letsch, A. Busse, A. M. Asemissen, S. Bauer, I. W. Blau, W.-K. Hofmann, L. Uharek, E. Thiel, and C. Scheibenbogen A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS Blood, June 25, 2009; 113(26): 6541 - 6548. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Mukherjee, G. D. Basu, T. L. Tinder, D. B. Subramani, J. M. Bradley, M. Arefayene, T. Skaar, and G. De Petris Progression of Pancreatic Adenocarcinoma Is Significantly Impeded with a Combination of Vaccine and COX-2 Inhibition J. Immunol., January 1, 2009; 182(1): 216 - 224. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. de la Cruz-Merino, E. Grande-Pulido, A. Albero-Tamarit, and M. E. Codes-Manuel de Villena Cancer and Immune Response: Old and New Evidence for Future Challenges Oncologist, December 1, 2008; 13(12): 1246 - 1254. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Cheung, M. J.P. DuPage, H. K. Dong, J. Chen, and T. Jacks Regulated Expression of a Tumor-Associated Antigen Reveals Multiple Levels of T-Cell Tolerance in a Mouse Model of Lung Cancer Cancer Res., November 15, 2008; 68(22): 9459 - 9468. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Madan, J. L. Gulley, J. Schlom, S. M. Steinberg, D. J. Liewehr, W. L. Dahut, and P. M. Arlen Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy Clin. Cancer Res., July 15, 2008; 14(14): 4526 - 4531. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. T. Garnett, J. Schlom, and J. W. Hodge Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement Clin. Cancer Res., June 1, 2008; 14(11): 3536 - 3544. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Schlom, J. L. Gulley, and P. M. Arlen Paradigm Shifts in Cancer Vaccine Therapy Experimental Biology and Medicine, May 1, 2008; 233(5): 522 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yokokawa, V. Cereda, C. Remondo, J. L. Gulley, P. M. Arlen, J. Schlom, and K. Y. Tsang Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer Clin. Cancer Res., February 15, 2008; 14(4): 1032 - 1040. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Mitchell In Reply J. Clin. Oncol., October 10, 2007; 25(29): 4693 - 4695. [Full Text] [PDF] |
||||
![]() |
G. C. Prendergast Recent Movement to Exploit Key Signaling Molecules and Cancer Vaccines Cancer Reviews Online Content, August 1, 2007; 2007(5): 9 - 9. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |